Skin Cancer Research - Penn State Cancer Institute
Skin Cancer Research
Research into skin cancer at Penn State Cancer Institute is conducted by the melanoma and skin cancer team. See current clinical trials and members of that team here.
Clinical Trials
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC)
The COVID-19 and Cancer Consortium (CCC19) Registry
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients (PSCI 21-190) (PH-L19IL2TNF-01/18)
The Collection of Blood, Tissue and Phenotypic Data in Patients Diagnosed with Skin Cancers and Subsequent Metastases for Inclusion in a Repository and Use in Outcome Studies
A Retrospective Evaluation to Understand how â-adrenergic Antagonism Impacts the Progression of Melanoma and the Efficacy of Standard Treatments Intended to Eliminate the Cancer
Disease Team Members
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
 |
Bryan | Anderson | MD | ||
 |
Elizabeth | Billingsley | MD | ||
 |
Amanda | Cooper | MD | ||
 |
Joseph | Drabick | MD | ||
 |
Neerav | Goyal | MD, MPH | ||
 |
Diane | Hershock | MD, PhD | ||
 |
Colette R. | Pameijer | MD | ||
 |
Christie | Travelute | MD |
Research into skin cancer at Penn State Cancer Institute is conducted by the melanoma and skin cancer team. See current clinical trials and members of that team here.
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC)
The COVID-19 and Cancer Consortium (CCC19) Registry
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients (PSCI 21-190) (PH-L19IL2TNF-01/18)
The Collection of Blood, Tissue and Phenotypic Data in Patients Diagnosed with Skin Cancers and Subsequent Metastases for Inclusion in a Repository and Use in Outcome Studies
A Retrospective Evaluation to Understand how â-adrenergic Antagonism Impacts the Progression of Melanoma and the Efficacy of Standard Treatments Intended to Eliminate the Cancer
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
|
Bryan | Anderson | MD | ||
|
Elizabeth | Billingsley | MD | ||
|
Amanda | Cooper | MD | ||
|
Joseph | Drabick | MD | ||
|
Neerav | Goyal | MD, MPH | ||
|
Diane | Hershock | MD, PhD | ||
|
Colette R. | Pameijer | MD | ||
|
Christie | Travelute | MD |